Tag : Infliximab

Gastroenterology

Underpowered PANTS: a response to the conclusions of “Extended Analysis Identifies Drug-Specific Association of Two Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab”

Newsemia
Underpowered PANTS: a response to the conclusions of “Extended Analysis Identifies Drug-Specific Association of Two Distinct HLA Class II Haplotypes for Development of Immunogenicity to...
Latest News

European Commission grants marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima® SC, for an additional five indications including for use in inflammatory bowel disease and ankylosing spondylitis

Newsemia
INCHEON, South Korea–(BUSINESS WIRE)–Celltrion Healthcare today announced that the European Commission (EC) has granted marketing authorisation for Remsima® (infliximab, CT-P13) subcutaneous (SC) formulation for the...
Pharma / Biotech

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Infliximab in Pediatric Inflammatory Bowel Disease: A Systematic Review and Revised Dosing Considerations.

Newsemia
Related Articles Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Infliximab in Pediatric Inflammatory Bowel Disease: A Systematic Review and Revised Dosing Considerations. J Pediatr Gastroenterol Nutr. 2020...
Gastroenterology

Extended Analysis Identifies Drug-Specific Association of Two Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab

Newsemia
Extended Analysis Identifies Drug-Specific Association of Two Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab Source link...
Gastroenterology

P092 COMPARISON OF INFLIXIMAB AND ADALIMUMAB CONCENTRATIONS BETWEEN THE ENZYME-LINKED IMMUNOSORBENT ASSAY AND THE HOMOGENEOUS MOBILITY SHIFT ASSAY (HMSA) IN INFLAMMATORY BOWEL DISEASE: AN UPDATE FOLLOWING IMPLEMENTATION OF CORRECTIVE MEASURES FOR THE HMSA

Newsemia
We previously showed a discrepancy between a commercially available enzyme-linked immunosorbent assay (ELISA) and the homogenous mobility shift assay (HMSA) for both infliximab and adalimumab...
Latest News

Nuovi dati dimostrano la non inferiorità dell’efficacia della formulazione sottocutanea di CT-P13 (infliximab biosimilare) rispetto alla formulazione endovenosa di CT-P13 in pazienti con artrite reumatoide

Newsemia
ATLANTA–(BUSINESS WIRE)–Oggi al meeting annuale dell’American College of Rheumatology (ACR), Celltrion Healthcare ha annunciato dati provenienti da uno studio di ricerca ulteriore sull’efficacia, la farmacocinetica...
Latest News

Nuevos datos demuestran la no-inferioridad en la eficacia de la fórmula subcutánea de CT-P13 (biosimilar de infliximab) respecto a la fórmula intravenosa de CT-P13 en personas con artritis reumatoide

Newsemia
ATLANTA–(BUSINESS WIRE)–Celltrion Healthcare ha anunciado hoy en el Congreso Anual del American College of Rheumatology (ACR), los datos de un estudio que investiga en mayor...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy